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Objectives: This study aimed at characterizing the nature, severity, and timing of nasal and
ocular symptoms in subjects with work-exacerbated asthma (WEA).
Methods: Among the 363 subjects referred to a tertiary-care hospital for the investigation of
work-related asthma symptoms, 105 subjects who demonstrated non-specific bronchial hyper-
responsiveness to histamine, but a negative response to a specific inhalation challenge with
the suspected occupational agent(s) were considered as having WEA. Their characteristics
were compared with those of 172 subjects with occupational asthma (OA), ascertained by
a positive response to a specific inhalation challenge.
Results: A high proportion of subjects with WEA (83%) and OA (90%) reported at least one nasal
symptom at work. Sneezing/itching and rhinorrhea were more frequent in subjects with OA
(78% and 70%, respectively) than in those with WEA (61%, p Z 0.004 and 57%, p Z 0.038,
respectively), while post-nasal discharge was more common in WEA (30%) than in OA (18%,
p Z 0.019). Nasal symptoms were less severe in WEA (median [25the75th percentiles] global
severity score: 4 [2e6]) as compared to OA (5 [4e7], p < 0.001). Nasal symptoms preceded less
frequently those of asthma in subjects with WEA (17%) than in subjects with OA (43%,
p Z 0.001).
Conclusions: Nasal symptoms are highly prevalent in subjects with WEA, although their clinical
pattern differs from that found in OA. Further investigations of the health and socio-economic
impacts of upper airways symptoms in WEA are required to improve the understanding and
management of this common condition.
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498 O. Vandenplas et al.Introduction performed (n Z 2). Fifty-seven subjects who showedDespite the increased emphasis on the relationships
between rhinitis and asthma,1 the interactions between the
upper and lower airways have been scarcely explored in the
context of the workplace environment.2 Work-related
asthma symptoms can be caused by workplace sensitizing
agents through immunologically-mediated mechanisms (i.e.
‘occupational asthma’) or triggered by irritants or physical
stimuli at the workplace (i.e. ‘work-exacerbated asth-
ma’).3e5 A substantial proportion (13e58%) of asthmatic
subjects experiences worsening of their asthma symptoms at
work. Nevertheless, 36e58% of these subjects fail to
demonstrate significant work-related changes in the physi-
ological indices of asthma.3e5 Work-exacerbated asthma
(WEA) refers to the worsening of symptoms temporally
related to work in subjects with pre-existing or coincident
asthma that was not caused by their workplace environ-
ment.3e5 There is emerging evidence that WEA represents
an important societal burden due to its high prevalence4 and
socio-economic impact.6,7 It has been documented that
work-related rhinitis symptoms are highly prevalent among
subjects with occupational asthma (OA)8 and that they often
precede the development of asthma symptoms.8e10 To our
knowledge, upper airway symptoms have never been
specifically evaluated in subjects with WEA.
The aim of this study was to characterise the nature,
severity, and timing of work-related nasal symptoms among
subjects experiencing WEA as compared to OA.Methods
Subjects
Subjects referred to a tertiary clinic for the evaluation of
work-related asthma symptoms were prospectively assessed
through a questionnaire on work-related nasal and ocular
symptoms. The diagnostic assessment included a detailed
medical and occupational history11 as well as skin-prick tests
with a battery of common inhalant allergens to identify
atopy, defined as a positive skin reaction to at least one
common allergen. All subjects completed specific inhalation
challenges (SICs) with the suspected occupational agent(s).
A diagnosis of OA was established through a positive SIC. A
diagnosis of WEA was kept if the SIC was negative, but the
histamine PC20 was16mg/ml. If both the histamine and the
specific inhalation challenges were negative, the subjects
were categorised as having ‘‘neither OA nor asthma’’.
The study included 105 subjects with WEA and 172
subjects with OA. Of the 363 initially eligible subjects, 29
subjects were excluded from the study because the results
of SIC could not be interpreted accurately for the following
reasons: (1) SIC with occupational agents elicited non-
reproducible changes in forced-expiratory volume in 1 s
(FEV1) (n Z 20); (2) SIC was associated with an increase in
non-specific bronchial responsiveness to histamine without
significant changes in FEV1 (n Z 7); or (3) the agent or
industrial process that was suspected of provoking asthma
symptoms could not be reproduced reliably in the labora-
tory and challenge test at the workplace could not beneither OA nor asthma were not considered in the analysis
of the data.
Questionnaire
The questionnaire on nasal symptoms was administered by
one physician (OV) before performing any other objective
tests. The questionnaire collected information on the
nature of the work-related nasal symptoms (sneezing/
hitching, rhinorrhea, blockage, post-nasal drip) and the
ocular symptoms (itching, redness, lacrimation). The
severity of the nasal symptoms e with the exception of
post-nasal drip e was graded on a scale from 0 to 3; 0: no
symptoms; 1: mild; 2: moderate; 3: severe. An overall
severity score ranging from 0 to 9 was calculated by
summing the individual scores. The questionnaire also
inquired about the temporal relationship between nasal
symptoms and the onset of asthma symptoms; before, at
the same time, after.
Specific inhalation challenges
The SICs were performed according to a previously
described methodology12 and international recommenda-
tions.13 On the first day, the subjects were exposed to
a control substance to ensure that there was no significant
fluctuation of FEV1. Spirometry
14,15 was obtained before
exposure and reassessed every 15 min for the first hour,
every 30 min for the second hour and then hourly for a total
of at least 6 h. On subsequent days, the subjects were
challenged with the occupational agent(s) suspected of
causing the work-related asthma symptoms based on the
occupational history and an inspection of the workplace by
hygienists from the Workers’ Compensation Board. Expo-
sure to occupational agents was generated in different
ways in order to reproduce, as closely as possible, the
conditions of exposure (e.g. temperature, dust, aerosol,
vapour or fume) encountered at the workplace. The dura-
tion of exposure was gradually increased to a total of 2 h on
the first challenge day. The FEV1 was measured for at least
6 h post-challenge at the same intervals as on the control
day. In the absence of any significant change in FEV1,
challenge exposure was repeated for 2e3 h on the following
day. The concentration of histamine causing a 20% fall in
FEV1 (PC20) value
16 was determined at the end of the
control day and reassessed 6e8 h after the end of each
challenge exposure in the absence of a significant change in
airway calibre. Additional challenge(s) on subsequent days
were proposed to the subjects who showed a significant
(3-fold) decrease in post-challenge histamine PC20 as
compared with the control day value.17 A SIC result was
considered positive when a sustained 20% fall in FEV1 was
recorded on two consecutive assessments.
Analysis of results
Quantitative data are presented as median with 25th and
75th percentiles. Comparison between subjects with WEA
and those with OA was made using the Chi-squared test for
categorical variables and Wilcoxon rank-sum test for
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using the SPSS 16.0 software (SPSS Inc, Chicago, Ill, USA). A
p-value <0.05 was considered as significant.
Results
Demographic and clinical characteristics
A diagnosis of OA was confirmed by SIC in 172 subjects,
whereas 105 subjects with a negative SIC were considered
as having WEA (Table 1). Subjects with WEA showed very
similar features pertaining to asthma outcomes compared
to those suffering from OA. They were more frequently ex-
smokers and less often never smokers. The interval of time
between the last work exposure and the diagnostic evalu-
ation was shorter in subjects with OA (median [25th and
75th percentile]: 2 [0.1e13] months) than in subjects with
WEA (10 [0.1e20] months). HMW agents were less often
involved in WEA (23%) than in OA (64%, p < 0.001).
Nasal and ocular symptoms
The characteristics of work-related nasal and ocular
symptoms among subjects with WEA and OA are presentedTable 1 Subjects’ baseline demographic and clinical character
Characteristics Work-exacer
(n Z 105) n
Sex (male) 64 (61)
Age, yrsa 41 (30e50)
Smoking status, current/ex/never 28/27/50 (2
Atopy 52 (50)





Inhaled short-acting beta2-agonist 62 (59)
Inhaled long acting beta2-agonist 37 (36)
Inhaled corticosteroid 70 (67)
Daily dose of inhaled corticosteroids, mga 800 (0e1875
Oral corticosteroid 14 (14)
Oral H1-antihistamine 30 (29)






Metals and welding 1
Woods 20
Enzymes 1
Cleaning agents and biocides 11
Persulfate salts 13
Paints, resins, and glues 14
Various LMW agents 6
Various HMW agents 2
Data are presented as n (%) unless otherwise specified.
a Median (25the75th percentiles); FEV1 % pred: forced-expiratory
provocative concentration of histamine causing a 20% fall in FEV1; HM
statistically significant.in Table 2. Nasal symptoms were highly prevalent in both
conditions as 83% of subjects with WEA and 90% of those
with OA reported that they experienced at least one work-
related nasal symptom. However, a lower proportion of
subjects with WEA experienced two or more nasal symp-
toms at work (67%) as compared to subjects with OA (78%,
pZ 0.034). Symptoms of conjunctivitis were less common,
being reported by 59% subjects with WEA and 63% of those
suffering from OA.
Sneezing/itching and rhinorrhea were more frequent in
subjects with OA (78% and 70%, respectively) than in
those with WEA (61%, p Z 0.004 and 57%, p Z 0.038,
respectively), while post-nasal discharge was more
common in WEA (30%) than in OA (18%, p Z 0.019). The
nasal symptoms’ median (25the75th percentiles) severity
score was lower in WEA (4 [2e6]) as compared to OA (5
[4e7], p < 0.001). Symptoms of rhinitis less frequently
preceded those of asthma in subjects with WEA (12 of 71,
17%) than in subjects with OA (57 of 133, 43%, pZ 0.001).
Among the subjects in whom the symptoms of rhinitis
occurred before those of asthma, the median interval of
time in the 12 subjects with WEA (8 [4e42] months) was
not different than in the 57 subjects with OA (24 [11e60]
months). The duration of workplace exposure before the
































volume in 1 s expressed as percent of predicted value; PC20:
W: high molecular weight; LMW: low molecular weight; NS: not
Table 2 Pattern of nasal and ocular symptoms.
Characteristics Work-exacerbated asthma
(n Z 105) n (%)
Occupational asthma
(n Z 172) n (%)
P value
Nasal symptoms
Sneezing/itching 64 (61) 134 (78) 0.004
Rhinorrhea 60 (57) 120 (70) 0.038
Obstruction 63 (60) 113 (66) NS
Post-nasal discharge 32 (30) 31 (18) 0.019
 1 symptom 87 (83) 154 (90) NS
 2 symptoms 70 (67) 135 (78) 0.034
3 symptoms 30 (29) 78 (45) 0.008
Global score (0e9 scale)a 4 (2e6) 5 (4e7) <0.001
Duration of work exposure before
onset of nasal symptoms, moa
74 (9e180) 65 (32e128) NS
Timing of nasal symptoms in relation with the onset of asthma
Before 12 (17) 57 (43) <0.001
At the same time 58 (82) 75 (56)
After 1 (1) 1 (1)
Unknown 16 (18) 21 (14) NS
Interval between rhinitis and asthma, moa 8 (4e42) 24 (11e60) NS
Duration of rhinitis symptoms at worka 21 (10e58) 52 (22e105) <0.001
Ocular symptoms
Itching 54 (51) 102 (59) NS
Redness 35 (33) 74 (43) NS
Lacrimation 29 (28) 57 (33) NS
 1 symptom 62 (59) 109 (63) NS
 2 symptoms 43 (41) 87 (51) NS
3 symptoms 13 (12) 37 (22) NS
Data are presented as n (%) unless otherwise specified.
a Median (25th-75th percentiles); NS: not statistically significant.
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nostic evaluation was shorter in subjects with WEA (21
[10e58]) than in those with OA (52 [22e105] months,
p < 0.001).
OA caused by HMW agents was more frequently associ-
ated with the presence of nasal symptoms (99%) than OA
due to LMW agents (73%, p < 0.001) (Table 3). Sneezing,
rhinorrhea and nasal obstruction were more common in
subjects with OA due to HMW agents (92%, 81%, 72%,
respectively) than in those with OA caused by LMW agents
(53%, p < 0.001; 50%, p < 0.001; and 55%, p Z 0.030,
respectively). Itching and redness of the eyes were also
more frequent for HMW (69% and 51%, respectively) than
LMW agents (42%, p Z 0.001 and 29%, p Z 0.006, respec-
tively). The nasal symptoms induced by HMW agents were
significantly more severe (global severity score: 6 [4e7])
than those induced by LMW agents (4 [0e6], p < 0.001).
Nasal symptoms appeared more frequently before those of
asthma in subjects exposed to HMW agents (48%) compared
to LMW agents (28%, pZ 0.013). Among subjects with WEA,
there were only slight differences between the pattern of
nasal and ocular symptoms induced by HMW and LMW
agents. Subjects with WEA exposed to HMW agents reported
more frequently that they experienced at least one nasal
symptom at work (100%) than those exposed to LMW agents
(78%, pZ 0.011), while a similar proportion in both groups
reported two or more nasal symptoms (71% vs 65%). Nasal
symptoms appeared more frequently before those ofasthma in subjects exposed to HMW agents (32%) compared
to LMW agents (12%, p Z 0.046).Discussion
This study showed that work-related nasal symptoms are
highly prevalent among subjects with WEA. Nasal symp-
toms were almost as common in subjects with WEA as in
those with demonstrable OA. Eighty-three percent of
subjects with WEA and 90% of those with OA reported at
least one work-related rhinitis symptom. Nevertheless,
a slightly lower proportion of subjects with WEA (67%) than
OA (78%) experienced two or more nasal symptoms at
work, which has been proposed as a clinical definition of
rhinitis.18 There is a dearth of information on upper airway
disorders in subjects with WEA. Malo and co-workers8
reported that symptoms of rhinitis were less common
(67%) in subjects in whom the diagnosis of OA was dis-
carded through a combination of SICs and/or peak expi-
ratory flow monitoring than in those with OA ascertained
by a positive response to SIC (92%). However, the inves-
tigators did not provide detailed information on the
pattern of nasal symptoms in subjects with a negative SIC.
In this study, the prevalence of nasal symptoms in subjects
with a negative SIC was higher than that reported by Malo
and co-workers, although the populations and the diag-
nostic criteria were similar.
Table 3 Comparison of nasal and ocular symptoms induced by HMW and LMW agents.
Characteristics Work-exacerbated asthma Occupational asthma
LMW (n Z 81)
n (%)
HMW (n Z 24)
n (%)
P value LMW (n Z 62)
n (%)




Sneezing/itching 48 (59) 16 (67) NS 33 (53) 101 (92) <0.001
Rhinorrhea 45 (56) 15 (62) NS 31 (50) 89 (81) <0.001
Obstruction 45 (56) 18 (75) NS 34 (55) 79 (72) 0.030
Post-nasal discharge 26 (32) 6 (25) NS 12 (19) 19 (17) NS
 1 symptom 63 (78) 24 (100) 0.011 45 (73) 109 (99) <0.001
 2 symptoms 53 (65) 17 (71) NS 34 (55) 101 (92) <0.001
3 symptoms 22 (27) 8 (33) NS 19 (31) 59 (54) 0.004
Global score (0e9 scale)a 4 (2e6) 4 (2e6) NS 4 (0e6) 6 (4e7) <0.001
Duration of work exposure before
onset of nasal symptoms, moa
111 (10e212) 25 (3e89) 0.034 68 (14e161) 62 (36e118) NS
Timing of nasal symptoms in relation with the onset of asthma: (nZ63:24/45:109)
Before 6 (12) 6 (32) 0.046 10 (28) 47 (48) 0.013
At the same time 45 (86) 13 (68) 26 (72) 49 (50)
After 1 (2) 0 (0) 0 (0) 1 (1)
Does not remember 11 (18) 5 (21) NS 9 (20) 12 (11) NS
Interval between rhinitis
and asthma, moa
8 (3e36) 13 (4e69) NS 16 (6e42) 30 (12e60) NS
Duration of rhinitis symptoms
at work, moa
22 (12e67) 12 (4e45) NS 36 (19e71) 56 (24e133) 0.049
Ocular symptoms
Itching 38 (47) 16 (67) NS 26 (42) 76 (69) 0.001
Redness 26 (32) 9 (38) NS 18 (29) 56 (51) 0.006
Lacrimation 23 (28) 6 (25) NS 17 (27) 40 (36) NS
 1 symptom 44 (54) 18 (75) NS 31 (50) 78 (71) 0.008
 2 symptoms 32 (40) 11 (46) NS 23 (37) 64 (58) 0.011
3 symptoms 11 (14) 2 (8) NS 7 (11) 30 (27) 0.020
Data are presented as n (%) unless otherwise specified.
a Median (25the75th percentiles); HMW: high molecular weight; LMW: low molecular weight; NS: not statistically significant.
Work-related rhinitis and asthma 501The results of this study show that there are noticeable
differences in the pattern of nasal symptoms between WEA
and OA. Subjects with WEA experienced more often post-
nasal discharge and less often sneezing/itching than those
suffering from OA. In addition, nasal symptoms were less
severe in WEA and less often preceded the onset of asthma
symptoms as compared with OA. Our finding that the
nature, severity, and timing of nasal symptoms differed in
WEA and OA provides further evidence that different
pathophysiological mechanisms are involved in the devel-
opment of these two conditions. Previous clinical studies
indicated that subjects with WEA and OA are very similar in
terms of asthma severity, medical resource utilization, and
adverse socio-economic impacts.7,19,20 However, the
majority of subjects with OA show increased numbers of
eosinophils in sputum and nasal lavage samples after
exposure to the causal agent, supporting an immunologi-
cally-mediated hypersensitivity response.21e23 In contrast,
the pathophysiological mechanisms underlying WEA and
associated nasal symptoms remain largely unknown. It now
widely acknowledged that a wide variety of conditions at
work can exacerbate asthma symptoms, including chem-
icals and physical stimuli, through a presumably non-
specific irritant effect.4 Recent research in animal modelssuggests that neurogenic inflammatory processes might
play an important role in the induction of heightened
airway sensitivity to chemical and physical stimuli.24 Non-
eosinophilic inflammation of the airways might also be
involved in the development of WEA since some subjects
with this condition show an increase in sputum neutrophils
after exposure to the suspected agents at work21 or in the
laboratory.22 Furthermore, one follow-up study indicated
that avoidance of the offending exposure results in an
improvement of asthma symptoms and medications usage
that, unlike OA, was unrelated to changes in functional
indices, but was associated with a decrease in sputum
neutrophils.20
Clinical and epidemiological studies have documented
that occupational rhinitis often precedes the onset of OA,2
especially in the case of HMW agents (58%) as compared to
LMW agents (25%).8 In this study, nasal symptoms
preceded less frequently those of asthma in subjects with
WEA (17%) than in those with OA (43%). This temporal
pattern is less consistent with a stepwise IgE-mediated
sensitization process extending from the upper to the
lower airways. In addition, these data indicate that work-
related nasal symptoms are much less relevant as an early
clinical marker for the development of subsequent work-
502 O. Vandenplas et al.related asthma symptoms in WEA than in OA. Neverthe-
less, the interactions between the upper and lower
airways should be further characterized in non-allergic
disorders, as recently outlined for non-occupational
conditions.25
There is accumulating evidence that rhinitis can exert
substantial adverse effects on the patients’ quality of
life,26,27 work productivity28 asthma control, and asthma-
related utilization of healthcare resources.29,30 By contrast,
the socio-economic consequences of work-related rhinitis
have received little attention.2 A retrospective cohort
study of bakers found a higher rate of job changes among
those experiencing nasal symptoms than the general pop-
ulation.31 A survey of greenhouse workers sensitized to bell
pepper pollen showed that occupational rhinitis was asso-
ciated with an impact on rhinitis-specific quality of life that
was similar to perennial rhinitis for the domains related to
nasal symptoms, sleep disturbance, and practical prob-
lems.32 The high prevalence of rhinitis symptoms in
subjects with WEA in this study outlines the need for
investigating their health and socio-economic impacts,
although nasal symptoms seem to be less severe in WEA
than in OA.
The major limitation of this study results from the
absence of consensus criteria for defining WEA. In most
epidemiological surveys, the definition of WEA relied on
self-reported symptoms temporally related to work, but
not on changes in the physiological indices of asthma. In
this study, as in previous clinical studies,7,19,20 a negative
response to SIC in subjects with non-specific bronchial
hyperresponsiveness to histamine was used as a proxy for
WEA. although the underlying pathophysiological mech-
anisms were unknown. The use of the SIC as a criterion
for distinguishing WEA from OA may be questioned
because this procedure can result in false-negative
results and a misclassification of OA as WEA. However,
such misclassification is likely to be minimal in our pop-
ulation and unlikely to have affected the results.
Therefore, the subjects were challenged with the sus-
pected occupational agent(s) for prolonged periods (i.e.
at least 4 h) before excluding a diagnosis of OA and the
changes in the level of non-specific hyperresponsiveness
to histamine were assessed after challenge exposures
that failed to elicit an asthmatic reaction. In addition,
subjects with indeterminate results of SIC and those for
whom the SIC in the laboratory could not adequately
reproduce the mode of exposure at work were excluded
from the analysis.
In conclusion, this study shows that nasal symptoms are
highly prevalent in subjects with WEA, although their clin-
ical pattern is different in WEA and OA. These findings
provide further support for characterizing the nature and
magnitude of the interactions between the upper and lower
airways in order to improve the understanding and
management of WEA.Funding
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